Symposia Archive (Page)
https://www.swisstph.ch/de/about/events/symposia-archive
Spring Symposium 2017 - Evidence Meets Decisions Makers Winter Symposium 2016 - Building on Success: Malaria Control and Elimination Spring Symposium 2016 - The Future of Travel Medicine Winter Symposium 2015 [...] Europe and Central Asia: Where do we stand and where to go? Autumn Symposium 2012 - Challenges in Malaria Research: Progress Towards Elimination Spring Symposium 2012 - eHealth in Proof and Practice: Op
Summer Symposium 2018 (Page)
https://www.swisstph.ch/de/about/events/summer-symposium-2018
Clinical Research Worlds – Approaches and Challenges Moderator: Wiweka Kaszubska, Medicines for Malaria Venture, Geneva, Switzerland 11:15 The Big Pharma Approach and Future Developments, Anthony Man, [...] Clinical Practice, Brussels, Belgium 14:00 Working in a PDP Business Model, David Reddy, Medicines for Malaria Venture, Geneva, Switzerland 14:30 The Future of Drug Development, Djordje Filipovic, Novartis I
A new WHO bottle bioassay method to assess the susceptibility of mosquito vectors to public health insecticides: results from a WHO-coordinated... (Publications)
BACKGROUND: The continued spread of insecticide resistance in mosquito vectors of malaria and arboviral diseases may lead to operational failure of insecticide-based interventions if resistance is not [...] be widely used to monitor baseline insecticide susceptibility of wild populations of vectors of malaria and Aedes-borne diseases worldwide.
Gene Coverage Count and Classification (GC3): a locus sequence coverage assessment tool using short-read whole genome sequencing data, and its... (Publications)
BACKGROUND: The ability of malaria rapid diagnostic tests (RDTs) to effectively detect active infections is being compromised by the presence of malaria strains with genomic deletions at the hrp2 and hrp3
Significant geographical differences in prevalence of mutations associated with <em>Plasmodium falciparum</em> and <em>Plasmodium vivax</em> drug... (Publications)
resistance remains a major obstacle to malaria treatment and control. It can arise and spread rapidly, and vary substantially even at sub-national level. National malaria programmes require cost-effective and
A 39-amino-acid C-terminal truncation of GDV1 disrupts sexual commitment in<em> Plasmodium falciparum</em> (Publications)
Malaria is a mosquito-borne disease caused by apicomplexan parasites of the genus Plasmodium. Completion of the parasite's life cycle depends on the transmission of sexual stages, the gametocytes, from [...] important to sustain GDV1 protein levels and thereby sexual commitment.IMPORTANCE Transmission of malaria-causing Plasmodium species by mosquitos requires the parasite to change from a continuously growing
Acceptability - a neglected dimension of access to health care: findings from a study on childhood convulsions in rural Tanzania (Publications)
especially in trans-cultural communication, for example if childhood convulsions are not linked with malaria and local treatment practices are mostly preferred. The study was linked to health interventions [...] ns which explicitly aimed at increasing the match between local and biomedical understanding of malaria. Caregivers, mostly mothers, did not seek advice on where to take an ill child. This indicates that
Predictive value of clinical and laboratory features for the main febrile diseases in children living in Tanzania: a prospective observational study (Publications)
also found: malaria could be ruled in by recent travel, typhoid by jaundice, radiological pneumonia by very fast breathing and UTI by fever duration of > /=4 days. The CART model for malaria included t
Operational Framework for Integrated Vector Control (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/operational-framework-for-integrated-vector-control
Aims Our goal is to develop strategies for the integrated management of vectors transmitting malaria and other major vector borne for decision making at the country level. Methods We propose to develop
Inhibitors of plasmodial serine hydroxymethyltransferase (SHMT): cocrystal structures of pyrazolopyrans with potent blood- and liver-stage activities (Publications)
plausible explanation for lack of significant activity of the inhibitors in the in vivo Pb mouse malaria model